Ocumension Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Ocumension Therapeutics has been growing earnings at an average annual rate of 50.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 61.3% per year.
Informazioni chiave
50.6%
Tasso di crescita degli utili
92.5%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 5.6% |
Tasso di crescita dei ricavi | 61.3% |
Rendimento del capitale proprio | -11.7% |
Margine netto | -104.0% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For
Sep 21Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23Ripartizione dei ricavi e delle spese
Come Ocumension Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 310 | -323 | 409 | 109 |
31 Mar 24 | 278 | -351 | 416 | 117 |
31 Dec 23 | 246 | -380 | 423 | 124 |
30 Sep 23 | 227 | -399 | 429 | 141 |
30 Jun 23 | 208 | -418 | 435 | 159 |
31 Mar 23 | 184 | -411 | 405 | 172 |
31 Dec 22 | 159 | -403 | 374 | 184 |
30 Sep 22 | 124 | -393 | 340 | 180 |
30 Jun 22 | 90 | -383 | 305 | 175 |
31 Mar 22 | 73 | -322 | 279 | 172 |
31 Dec 21 | 56 | -260 | 254 | 169 |
30 Sep 21 | 44 | -426 | 237 | 194 |
30 Jun 21 | 32 | -593 | 220 | 220 |
31 Mar 21 | 23 | -1,429 | 252 | 200 |
31 Dec 20 | 13 | -2,265 | 284 | 180 |
30 Sep 20 | 8 | -2,540 | 242 | 150 |
30 Jun 20 | 2 | -2,816 | 200 | 121 |
31 Mar 20 | 1 | -2,064 | 130 | 110 |
31 Dec 19 | 0 | -1,312 | 60 | 99 |
Guadagni di qualità: 1477 is currently unprofitable.
Margine di profitto in crescita: 1477 is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 1477 is unprofitable, but has reduced losses over the past 5 years at a rate of 50.6% per year.
Accelerare la crescita: Unable to compare 1477's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: 1477 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Rendimento del capitale proprio
ROE elevato: 1477 has a negative Return on Equity (-11.66%), as it is currently unprofitable.